Researchers at MUSC Hollings Cancer Center have developed the ADLiB liquid biopsy platform, which uses machine learning to prioritize lymphoma diagnosis, identifying high-risk patients with up to 95% accuracy.
Foresight Diagnostics’ ctDNA-MRD testing has been included in the NCCN Clinical Practice Guidelines for diffuse large B-cell lymphoma.
Foresight Diagnostics CEO and CSO Jake Chabon gives an overview of what’s next for liquid biopsy testing, and how it will impact the continuum of care.
The automated PS-10 sample preparation system streamlines workflows and standardizes clinical flow cytometry testing.
Read MoreThe Aurora system is now available with five lasers, making it possible for researchers to visualize more than 30 colors from a single sample.
Read More
The biomarker may provide a cost-effective and efficient means to identify elevated ROS1 protein expression in cancer.
Read More
In a field where highly trained professionals interact on a daily basis with an ever-changing array of innovative technologies, new and useful ideas seem to be around every corner.
Read More
New 10-color system with Kaluza C software streamlines workflow and QC reporting for flow cytometry in leukemia and lymphoma analysis.
Read More
Nano-Signature Discovery Could Revolutionize Cancer Diagnosis A quick and easy test to...
Read More
Continued validation of Lophius’ development capabilities bodes well as the company advances into tuberculosis diagnostics as its next focus area.
Read More
The new technology has proved to be up to 90% accurate in tests involving 200 human cancer samples and normal DNA.
Read More
Droplet digital PCR can provide a more accurate assessment of low levels of BCR-ABL mRNA than quantitative real-time PCR.
Read More
Multidisciplinary guidance document focuses on specimen requirements for the diagnosis of lymphoma.
Read More
This month’s Product Spotlight features new products from such companies as Advanced Instruments, Beckman Coulter, and Thermo Fisher Scientific.
Read More
HTG’s next-generation sequencing assay enables subtyping of DLBCL as activated B-cell-like or germinal center B-cell-like.
Read More
Under a new grant from the National Cancer Institute, Advanced Cell Diagnostics will partner with the Cleveland Clinic to develop an ultrasensitive diagnostic test for B-cell lymphoma.
Read MoreA new collaboration plans to provide genomic profiling and information for patients that have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas, and myeloproliferative and myelodysplastic diseases.
Read MoreA new study shows the MultiOmyx profile could improve disease assessment for both diseases using multiplex proteins.
Read More